Leadership

Saad Harti

Saad Harti

Founder and CEO

Saad has started in the financial field, at Arthur Andersen.
He later co-founded Altacare, a healthcare business development firm active in more than 50 markets.
Saad has pioneered contraceptive-access programs in developing countries.
Saad is the founder of Legacy and manages the company.

Geert Cauwenbergh

Geert Cauwenbergh, Ph.D.

Partner

Geert founded Barrier Therapeutics, a dermatology company in 2001.
After bringing Barrier to success it was acquired by Stiefel in 2008. Prior to founding Barrier, Geert was responsible for the worldwide research and development of all skin care products for the Johnson & Johnson consumer companies.
He is a board member of several dermatology companies. He has authored more than 100 publications.
Geert is a shareholder of Legacy and acts as strategic and scientific advisor.

JiaWei Liu

JiaWei Liu, Ph.D.

VP R&D

Active in international academic and pharmaceutical industry,
JiaWei successfully developed quality research projects in Chinese Academy of Sciences, Geneva and Lausanne University Hospitals.
He was previously responsible for new drug search & evaluation Asia at the Swiss drug development company Debiopharm Group.
He also engaged in teaching activities at Harvard Medical School in 2013 and 2014.
As Legacy Healthcare’s Vice President, he is in charge of the company’s R&D activities.

Michel Chretienne

Michel Chretienne, Pharm D.

VP Quality

Michel has served as Pharmaceutical Director and Pharmacist in charge at Hoechst Marion Roussel (Aventis) until 1999.
Michel is involved in a number of professional and scientific societies such as the French Association of Regulatory Affairs,
Member of the Ethic Committee and Mediation of the French pharmaceutical industry (CEMIP) etc.
Michel is responsible of the quality and manufacturing affairs of Legacy.

Nadine Vincent

Nadine Vincent, Pharm D.

Head of Regulatory

Nadine has a pharmaceutical education and management training (INSEAD).
She spent 30 years at Hoechst Marion Roussel, first in Research & Development and then as International Strategic Regulatory manager in charge of registering the key anti-infective products.
She then joined HRA Pharma, where she stayed for over 15 years as Regulatory Affairs Director. Nadine has managed the registration of multiple products with EMA, FDA, PDMA, etc.
Nadine is in charge of Regulatory Affairs.

Marcos Val

Marcos Val

Chief Financial Officer

Marcos has spent over 15 years in corporate Healthcare and FMCG international finance leadership roles.
In particular with Medtronic, as part of his Europe & Canada director role he supported the Biopharma Organization set up : pioneers in the launch of multi-million spine and neurocience drug products.
Later in his career, he has successfully raised funds and coached healthcare startups while also carrying due diligence work for investor groups.

Bruce Patsner

Bruce Patsner, M.D., J.D.

North American Operations Director

Active in women’s cancer care and medical research in the United States and Asia for 30 years,
Bruce later trained in health law and Cal Berkeley and Harvard Law Schools; was a Senior Medical Officer at the United States FDA; and later worked in Pharmacovigilance at Genzyme/Sanofi in Cambridge, Massachusetts. He has extensive experience in clinical trial design and more than 100 publications in Oncology and food and drug law.
Bruce is the Director of North American Operations for Legacy.

Tadafumi Shiiba

Tadafumi Shiiba

General Manager Japan

Tadafumi Shiiba, 44, General Manager for Legacy Healthcare KK (Japan), has accumulated experience working for medical corporations for more than 15 years. He served as sales representative at KOLs level in the fields of orthopedic surgery and gastroenterology at Smith & Nephew and Suzuken in Japan.
He then joined Legacy Healthcare in 2012 first as a sales manager. He initially deployed CG 210 in several physician dispensing clinics and later on CG 428 in more than 60 oncology clinics. Thanks to his skills, Tadafumi managed to raise interest and convince two KOLs to conduct important self-funded clinical trials on the product in two hospitals in Japan.